FDA针对Foundayo的上市后监管要求明确指出,唯有通过临床试验才能充分识别药物可能引发的意外严重肝损伤风险。
FDA针对Foundayo的上市后监管要求明确指出,唯有通过临床试验才能充分识别药物可能引发的意外严重肝损伤风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.